Green tea compound tested to stop liver cancer before it starts
NCT ID NCT06015022
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 39 times
Summary
This study tests whether a green tea extract called EGCG can lower the risk of liver cancer in people with liver cirrhosis. Sixty adults with cirrhosis but no prior liver cancer will take either EGCG or a placebo for several months. Researchers will measure changes in a blood-based risk score to see if EGCG reduces cancer risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
epigallocatechin gallate (EGCG), a green tea extract
What this could lead to
If it works, this could point toward a simple, natural supplement to help prevent liver cancer in people with cirrhosis.
What could go wrong
This is a small, early-phase trial testing a biomarker, not cancer itself. The supplement may not reduce actual cancer risk, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.